CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-18 | Zalevsky Jonathan Chief R&D Officer | Sale | −186 | $71.98 | $13K | 9,570 |
| 2026-08-18 | ROBIN HOWARD W President & CEO | Sale | −418 | $71.98 | $30K | 54,627 |
| 2026-06-30 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −5,681 | $70.00 | $398K | 9,756 |
| 2026-06-17 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −5,500 | $60.81 | $334K | 59,545 |
| 2026-06-17 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −4,500 | $61.65 | $277K | 55,045 |
| 2026-06-16 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −5,303 | $59.97 | $318K | 69,742 |
| 2026-06-16 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −4,697 | $60.71 | $285K | 65,045 |
| 2026-06-15 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −5,538 | $60.71 | $336K | 15,437 |
| 2026-05-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −199 | $65.51 | $13K | 20,975 |
| 2026-05-19 | ROBIN HOWARD W President & CEO | Sale | −444 | $65.51 | $29K | 75,045 |
| 2026-02-18 | Zalevsky Jonathan Chief R&D Officer | Sale | −180 | $73.00 | $13K | 21,174 |
| 2026-02-18 | ROBIN HOWARD W President & CEO | Sale | −423 | $73.00 | $31K | 75,489 |
| 2026-01-20 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −3,867 | $35.67 | $138K | 21,354 |
| 2025-11-25 | Zalevsky Jonathan Chief R&D Officer | Sale | −1,157 | $54.28 | $63K | 18,971 |
| 2025-11-25 | Wilson Mark Andrew Chief Legal Officer | Sale | −630 | $54.28 | $34K | 21,585 |
| 2025-11-25 | ROBIN HOWARD W President & CEO | Sale | −2,207 | $54.28 | $120K | 54,245 |
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −2,100 | $45.16 | $95K | 53,908 |
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,200 | $46.41 | $56K | 52,708 |
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −2,156 | $47.49 | $102K | 50,552 |
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,210 | $48.18 | $58K | 49,342 |
Page 1 of 9 · 161 trades